Lilly offers weight-loss drugs in vials at a discount to fight competition
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .
Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...
Blue Harbor Entertainment will release the Patricia Clarkson-starring drama 'Lilly,' based on the true story of Lilly ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
5hon MSN
Eli Lilly ( LLY 2.11%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...
Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback